Multiple studies across many cancers have provided solid evidence about a positive correlation between PD-L1 expression and response to immunotherapy, so PD-L1 can be the biomarker to identify groups of patients who will benefit from these agents [25, 26]. This evidence concerns the gene CD274 and cancer.